Double-blind, randomized, placebo-controlled trial in subjects with ITP who are 'non-responders' at the maximum package insert dose (75mg) of eltrombopag; non-responders are those with platelet counts < 50,000 despite taking 75 mg/day of eltrombopag for at least 3 weeks.